Genotype Result Ingestion and Structuring
Receiving results from laboratories in varied formats and storing diplotypes and phenotypes as discrete data rather than as a scanned report or narrative text.
Custom Software
Hire Pharmacogenomics Engineers
Pharmacogenomics engineers build systems that translate genetic test results into medication guidance for clinicians. They handle diplotype interpretation, guideline implementation, result persistence across a patient’s lifetime, and delivery at prescribing, working so a pharmacist or prescriber makes every therapy decision.
Pharmacogenomic results differ from most lab data in one decisive way: they do not expire. A result obtained today remains relevant for every prescribing decision across the patient’s life, which means the engineering problem is durable storage and reliable resurfacing rather than one-time interpretation. Systems that treat the result as a report lose it. Taction Software builds for persistence, and our hire dedicated developers hub covers adjacent roles.
Tell Us Your Requirements
Our experts are ready to understand your business goals.
Trusted Partners
Trusted by Industry Leaders Worldwide
Recognition
Awards & Recognitions
What Pharmacogenomics Engineers Build
The value is realized at the moment of prescribing, potentially years after testing. That shapes everything: results must be structured, stored discretely, and surfaced when a relevant drug is ordered. The work below reflects that. Note how much concerns storage and resurfacing rather than interpretation, because interpretation follows published guidelines while lifetime persistence is where implementations usually fail.
Guideline-Based Interpretation Implementation
Implementing published gene-drug guidance faithfully, including phenotype assignment and the recommendation text those guidelines specify for each combination.
Prescribing-Time Decision Support
Surfacing relevant guidance when a drug with an established gene-drug interaction is ordered, which is the only moment the result changes care.
Lifetime Result Persistence and Resurfacing
Ensuring results remain retrievable and continue firing across encounters, care settings, and years, since the clinical value accrues over a lifetime rather than at testing.
Guideline Version Management
Tracking which guideline version informed each piece of guidance, since recommendations are updated and a patient may need reassessment when they change.
Pharmacist Review Workflow
Routing complex or multi-drug situations to pharmacists with the genotype context assembled, since pharmacogenomic interpretation frequently requires their expertise.
Genomic and Clinical Context This Role Requires
Pharmacogenomics has more mature guidance than most genomic applications, with established gene-drug pairs and published recommendations. The difficulties are practical: laboratories report differently, allele coverage varies by test, and phenotype assignment depends on which alleles were examined. Engineers must understand these to avoid interpreting a result as more complete than it is. The context below spans the healthcare work you assign.
01
Test Coverage Determines Interpretation Validity
A genotype result reflects only the alleles tested. Assigning a phenotype without recording which alleles were covered overstates what the result establishes.
02
Laboratory Reporting Varies Substantially
Laboratories report star alleles, diplotypes, and phenotypes with different conventions. Ingestion must normalize without inferring beyond what the laboratory stated.
03
Allele Frequencies Differ Across Ancestries
Tests covering alleles common in one population may miss those common in another, which means a result carries different completeness depending on the patient’s ancestry.
04
Guidance Is Published and Should Be Followed
Established guidelines exist for many gene-drug pairs. Implementations should follow them faithfully rather than constructing local interpretation logic.
05
Alert Fatigue Applies Here Too
Firing on every drug with any genomic association produces noise. Guidance should surface where published recommendations indicate a meaningful action.
06
Prescribers and Pharmacists Decide Therapy
Guidance informs. Drug selection, dose adjustment, and alternative therapy decisions are made by the prescriber or pharmacist, who documents the reasoning.
Technical Skills for Pharmacogenomic Systems
This work is structured data engineering, rule implementation, and clinical workflow integration. The genomics is bounded and well documented; the difficulty is durable discrete storage and reliable resurfacing across systems and years. The competencies below reflect that. Weight discrete result modeling and CDS integration above genomic analysis, since results stored as documents deliver nothing at the moment of prescribing.
Discrete Genomic Result Modeling
Storing genes, alleles tested, diplotypes, and assigned phenotypes as queryable data with test provenance, rather than retaining the laboratory report as an attachment.
Laboratory Result Ingestion and Normalization
Handling varied laboratory formats and nomenclature, mapping to standard representations without inferring alleles or phenotypes the laboratory did not report.
Guideline Implementation and Version Control
Encoding published gene-drug recommendations with version tracking, so guidance reflects current guidance and historical decisions remain reconstructable.
Prescribing Workflow Integration
Delivering guidance through decision support at order entry. Our healthcare integration work covers the CDS and interface connectivity required.
Persistence Across Systems and Time
Ensuring results survive system migrations, care setting changes, and years of inactivity, which is where most pharmacogenomic implementations lose their value.
Coverage Transparency in Display
Showing which alleles were tested alongside any phenotype, so a clinician knows whether an absent variant was excluded or simply not examined.
How We Evaluate Pharmacogenomics Engineers
The distinguishing question is how results were stored. Engineers who kept them as discrete data understood that value accrues at future prescribing; those who stored reports built a document repository. Our assessment centers on discrete modeling, coverage transparency, and guideline fidelity. Our delivery process includes review points where you can reassess fit.
Result Storage Approach
We ask how genotype results were stored. Answers describing scanned reports or narrative text indicate a system that cannot fire guidance at prescribing.
Coverage Handling
We ask how they recorded which alleles were tested. Systems assigning phenotypes without coverage detail overstate what the result establishes clinically.
Guideline Fidelity
We ask which guidance they implemented and how faithfully. Engineers constructing local interpretation logic have made clinical decisions belonging to published guidance and pharmacists.
Resurfacing Across Time
We ask whether guidance still fired years after testing. Implementations that lose results at system boundaries deliver value once rather than for a lifetime.
Alert Volume Judgment
We ask how they limited firing. Systems alerting on every genomic association produce noise that leads clinicians to dismiss the meaningful recommendations too.
Verified Implementation Experience
We describe which pharmacogenomic systems each engineer built and what runs clinically. We do not claim pharmacy or genomic credentials for engineers who lack them.
Engagement Options for Pharmacogenomic Programs
Engagements should start with discrete result storage and a small number of high-value gene-drug pairs rather than with comprehensive coverage, because storage is the foundation and a few pairs deliver most of the near-term benefit. Structures below reflect that. We also confirm pharmacist availability, since pharmacogenomic programs without pharmacy involvement produce guidance nobody is positioned to interpret.
Discrete Storage Foundation First
Building structured result ingestion and persistence before interpretation. Without this, every subsequent capability is limited to the encounter where testing occurred.
A Small Set of Gene-Drug Pairs
Implementing guidance for a few well-established pairs delivers most of the early benefit while limiting alert volume and implementation scope considerably.
Engineer With Pharmacist Partnership
Pharmacogenomic interpretation is pharmacy expertise. Engagements pairing engineering with pharmacy produce guidance that reflects clinical practice rather than literal guideline text.
Augmenting Your Clinical Systems Team
Where you own the program, staff augmentation adds engineering capacity working within your existing decision support standards and governance.
Full Team for Genomic Medicine Programs
A dedicated healthcare development team suits programs spanning result ingestion, storage, interpretation, decision support, and pharmacist workflow.
Fixed-Scope Ingestion and Storage Build
Where the requirement is structured storage and retrieval rather than decision support, a fixed-scope build under our engagement models delivers it.
Tell Us Where Results Go Today
Share your testing volumes, which laboratories report to you, how results are currently stored, and your pharmacy involvement. Storage determines whether guidance can fire at all.
Interpretation Limits, Prescribing Authority, and Boundaries
Pharmacogenomic guidance influences medication decisions, which places it in decision support territory with the transparency obligations that carry. Where intended use may create diagnostic or treatment claims, SaMD classification is assessed during discovery. Taction holds no FDA clearance. We build to HIPAA-aligned practices where HIPAA applies; software cannot be HIPAA certified. Genetic information carries additional protections.
01
Prescribers and Pharmacists Decide Therapy
Guidance presents published recommendations. Drug selection, dosing, and alternatives are decided by the prescriber or pharmacist, who may deviate with documented reasoning.
02
Coverage Displayed With Every Phenotype
Which alleles were tested appears alongside any phenotype assignment, so clinicians know whether a normal result reflects testing or absence of testing.
03
Guidance Traced to Published Source
Every recommendation cites the guideline and version it derives from, so clinicians can review the basis rather than accepting an unattributed instruction.
04
Genetic Information Handling
Genomic data carries protections beyond ordinary clinical information, including implications for family members. Access controls and disclosure handling reflect that sensitivity.
05
Sensitive Prescribing Categories
Guidance touching psychiatric or substance use medications requires care about visibility. We built CHIPSS, a behavioral health system, where such segmentation was foundational.
06
Applications We Would Not Build
We would not build systems that alter prescriptions automatically, block therapy based on genotype without clinician override, or infer phenotypes from alleles a laboratory did not report.
Cost to Hire Engineers and Build Pharmacogenomic Capability
Cost concentrates in discrete storage architecture and decision support integration rather than in interpretation logic, which follows published guidance. Laboratory ingestion across varied reporting formats is the other substantial line. We publish no figures on prescribing changes or adverse event reduction, because those depend on your population, testing volumes, and prescribing patterns. What we deliver is instrumentation for your own measurement.
MVP or Single Module
$40,000 to $80,000
Discrete result ingestion and storage with interpretation for a small set of gene-drug pairs and decision support delivery at prescribing, with coverage transparency.
Full Platform Build
$80,000 to $200,000
Comprehensive pharmacogenomic capability with multi-laboratory ingestion, guideline version management, broader gene-drug coverage, pharmacist workflow, and persistence across systems.
Enterprise Deployment
Starting at $200,000
Multi-facility deployment with integration across clinical environments, governance documentation, and result portability. Cost scales with systems and gene-drug scope.
Discovery Phase Scoping
Discovery is paid and time-boxed. It produces a result storage assessment, laboratory format review, gene-drug prioritization, decision support feasibility finding, and an itemized fixed-scope estimate.
Cost Drivers to Expect
Laboratory count and format variety, gene-drug pair scope, decision support integration complexity, existing result storage state, pharmacy workflow requirements, and clinical governance cycles.
Ongoing Support Costs
Guidelines are updated and laboratories change reporting. Budget for guidance revision, ingestion maintenance, patient reassessment when recommendations change, and alert volume review.
Third-party licensing, cloud infrastructure, data subscriptions, and hardware are separate from engineering cost and itemised clearly.
Why Build Pharmacogenomic Capability With Taction
Two questions matter. Whether the vendor stores results as discrete lifetime data, and whether they display test coverage honestly. Taction Software has built healthcare software since 2013, more than twelve years, with over 200 healthcare projects delivered and ISO 27001 certification. Leadership brings more than twenty years of personal experience in the field, which is separate from company age. Our wider case for Taction sits elsewhere.
Clinical Data Modeling Depth
We built Voyant Health, an EHR platform. Our healthcare case studies reflect experience modeling clinical data for long-term retrieval and resurfacing.
Sensitive Data Segmentation Experience
We built CHIPSS, a behavioral health system, where access segmentation governed visibility. Genetic and psychiatric medication data require comparable controls.
Experience Under Regulatory Registration
We built Revive Ease and PainKare, both FDA-registered applications. That work informs how we document intended use where guidance influences prescribing.
ISO 27001 Certified Security Management
Taction Software holds ISO 27001 certification covering our information security management practices. It certifies our internal processes and does not determine your organization’s compliance position.
We Build Storage Before Interpretation
Discrete lifetime persistence is the foundation. Recommending that sequence means a less visible first deliverable and a program that actually delivers value years later.
We Will Recommend Fewer Gene-Drug Pairs
Implementing a few well-established pairs delivers most benefit with far less alert volume. That recommendation reduces our implementation scope substantially.
FAQs
Frequently Asked Questions
We review how results are currently stored, which laboratories report to you, your decision support environment, and your pharmacy involvement, then present matched candidates for your approval.
Storage with a small gene-drug set runs $40,000 to $80,000, comprehensive capability $80,000 to $200,000, and multi-facility deployment starts at $200,000. Licensing and infrastructure are itemized separately.
Our delivery history includes the Voyant Health EHR platform, the CHIPSS behavioral health system, and the FDA-registered applications Revive Ease and PainKare, within more than 200 healthcare projects delivered since 2013.
Because value accrues at future prescribing, potentially years later. Results stored as reports or narrative text cannot trigger guidance when a relevant drug is ordered.
No. It presents published guidance with its source and the alleles tested. Drug selection and dosing decisions remain with the prescriber or pharmacist, who may deviate with documented reasoning.
Pharmacogenomics addresses established gene-drug guidance with published recommendations. Precision medicine covers broader molecular interpretation, where evidence is less settled and curation is a larger part of the work.
Share your testing volumes, reporting laboratories, current result storage, decision support environment, pharmacy involvement, and the engagement model you have in mind. We will assess whether guidance can fire at prescribing today and prioritize storage if it cannot. We do not promise instant matching or any outcome figure.